ResMed Inc (RMD)
Pretax margin
| Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,677,570 | 1,264,800 | 1,101,660 | 960,483 | 883,662 |
| Revenue | US$ in thousands | 5,146,330 | 4,685,300 | 4,222,990 | 3,578,130 | 3,196,820 |
| Pretax margin | 32.60% | 27.00% | 26.09% | 26.84% | 27.64% |
June 30, 2025 calculation
Pretax margin = EBT ÷ Revenue
= $1,677,570K ÷ $5,146,330K
= 32.60%
The pretax margin of ResMed Inc has demonstrated a pattern of fluctuation over the specified period from June 30, 2021, to June 30, 2025. As of June 30, 2021, the pretax margin stood at 27.64%, indicating that approximately 27.64% of revenue was retained as profit before taxes. This margin experienced a slight decline in the following year, decreasing to 26.84% by June 30, 2022, reflecting a marginal deterioration in pre-tax profitability. The trend continued into June 30, 2023, with the margin further decreasing to 26.09%, suggesting ongoing pressures or increased costs impacting profitability.
However, the margin showed signs of stabilization and recovery in subsequent years, rising back to 27.00% by June 30, 2024. This near-return to the 2021 level indicates an improvement in pre-tax profitability or adjustments in cost structures. The most notable change is observed by June 30, 2025, where the pretax margin significantly increases to 32.60%. This substantial increase suggests an improvement in operational efficiency, cost management, or revenue growth relative to expenses, leading to a marked enhancement in pre-tax profitability for that year.
Overall, the pretax margin for ResMed Inc exhibits a pattern of initial decline, followed by stabilization and a notable uptrend in 2025, reflecting variations in the company's profitability margins driven by internal and external factors during this period.
Peer comparison
Jun 30, 2025